ECSP099608A - Preparacion solida que comprende alogliptina y pioglitazona - Google Patents

Preparacion solida que comprende alogliptina y pioglitazona

Info

Publication number
ECSP099608A
ECSP099608A EC2009009608A ECSP099608A ECSP099608A EC SP099608 A ECSP099608 A EC SP099608A EC 2009009608 A EC2009009608 A EC 2009009608A EC SP099608 A ECSP099608 A EC SP099608A EC SP099608 A ECSP099608 A EC SP099608A
Authority
EC
Ecuador
Prior art keywords
solid preparation
pioglitazona
alogliptina
compound
sugar
Prior art date
Application number
EC2009009608A
Other languages
English (en)
Inventor
Kenji Nakamura
Kenichiro Kiyoshima
Junya Nomura
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39240362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP099608(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of ECSP099608A publication Critical patent/ECSP099608A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona una preparación sólida que contiene el compuesto (I), en donde la definición del compuesto (I) es como se define en la descripción, y pioglitazona, que es útil como un fármaco terapéutico para diabetes o similar y superior en la propiedad de disolución, estabilidad química y estabilidad en la disolución. Una preparación sólida que contiene las siguientes primera y segunda partes: (1) la primera parte contiene el compuesto (I) o una de sus sales, como el primer excipiente, azúcar o alcohol de azúcar; y (2) la segunda parte contiene pioglitazona o una de sus sales y, como el segundo excipiente, azúcar o alcohol de azúcar.
EC2009009608A 2007-02-01 2009-08-31 Preparacion solida que comprende alogliptina y pioglitazona ECSP099608A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007023594 2007-02-01

Publications (1)

Publication Number Publication Date
ECSP099608A true ECSP099608A (es) 2009-09-29

Family

ID=39240362

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009608A ECSP099608A (es) 2007-02-01 2009-08-31 Preparacion solida que comprende alogliptina y pioglitazona

Country Status (38)

Country Link
US (1) US8637079B2 (es)
EP (1) EP2107905B1 (es)
JP (1) JP5284968B2 (es)
KR (1) KR101486091B1 (es)
CN (1) CN101646420B (es)
AR (1) AR065097A1 (es)
AT (1) ATE488227T1 (es)
AU (1) AU2008211981B2 (es)
BR (1) BRPI0807453B8 (es)
CA (1) CA2677201C (es)
CL (1) CL2008000279A1 (es)
CR (1) CR10992A (es)
CY (1) CY1111264T1 (es)
DE (1) DE602008003522D1 (es)
DK (1) DK2107905T3 (es)
DO (1) DOP2009000195A (es)
EA (1) EA015180B1 (es)
EC (1) ECSP099608A (es)
ES (1) ES2354397T3 (es)
GE (1) GEP20125410B (es)
HR (1) HRP20110094T8 (es)
IL (1) IL200108A (es)
JO (1) JO2650B1 (es)
MA (1) MA31169B1 (es)
ME (1) ME01239B (es)
MX (1) MX2009008100A (es)
MY (1) MY147596A (es)
NZ (1) NZ579008A (es)
PE (1) PE20081663A1 (es)
PL (1) PL2107905T3 (es)
PT (1) PT2107905E (es)
RS (1) RS51592B (es)
SI (1) SI2107905T1 (es)
TN (1) TN2009000317A1 (es)
TW (2) TWI453041B (es)
UA (1) UA95828C2 (es)
WO (1) WO2008093882A1 (es)
ZA (1) ZA200905621B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EA020870B1 (ru) * 2007-07-19 2015-02-27 Такеда Фармасьютикал Компани Лимитед Твердый препарат, включающий алоглиптин и гидрохлорид метформина
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
NZ604091A (en) 2008-08-15 2014-08-29 Boehringer Ingelheim Int Purin derivatives for use in the treatment of fab-related diseases
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
UY32126A (es) 2008-09-25 2010-04-30 Takeda Pharmaceutical Composición farmacéutica sólida
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
AU2010212823B2 (en) 2009-02-13 2016-01-28 Boehringer Ingelheim International Gmbh Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
JP5685550B2 (ja) 2009-02-13 2015-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
KR20240090632A (ko) * 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
AR082091A1 (es) * 2010-05-05 2012-11-14 Boehringer Ingelheim Int Composiciones farmaceuticas que comprenden pioglitazona y linagliptina y procedimiento de preparacion
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN103877054B (zh) * 2012-12-21 2016-05-25 北大方正集团有限公司 一种苯甲酸阿格列汀片剂及其制备方法
CN103156819A (zh) * 2013-03-29 2013-06-19 山东罗欣药业股份有限公司 苯甲酸阿格列汀组合物片剂及其制备方法
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
JP6027710B1 (ja) * 2014-12-25 2016-11-16 田辺三菱製薬株式会社 糖尿病治療用固形製剤
US10548848B2 (en) * 2015-06-17 2020-02-04 Hexal Ag Alogliptin formulation
RU2697836C2 (ru) 2015-06-26 2019-08-21 Кореа Юнайтед Фарм. Инк. Комбинированный препарат мозаприда и рабепразола
CN105030719B (zh) * 2015-08-20 2018-07-20 杭州成邦医药科技有限公司 一种含有阿格列汀和吡格列酮的组合物
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
KR102485766B1 (ko) 2019-12-11 2023-01-09 한국유나이티드제약 주식회사 생체이용률이 향상된 피오글리타존 함유 약학조성물
CN113925838B (zh) * 2021-11-11 2022-11-11 乐普制药科技有限公司 一种依帕司他与西格列汀或其可药用盐的复方缓释片及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
DK0559702T3 (da) 1990-11-27 1995-05-15 Byk Gulden Lomberg Chem Fab Urapidil-slow-release-præparat
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JP2931811B2 (ja) 1997-06-03 1999-08-09 ユニコロイド株式会社 徐放性カプセル
US6030641A (en) * 1997-06-03 2000-02-29 Uni Colloid Kabushiki Kaisha Sustained release capsule and method for preparing the same
DE19725911A1 (de) 1997-06-13 1998-12-17 Roland Prof Dr Bodmeier Zusammensetzungen, die die Wirkstofffreisetzung verzögern
AU8532798A (en) 1997-06-13 1998-12-30 Roland Bodmeier Compounds which delay the release of active substances
WO2000016776A1 (fr) 1998-09-18 2000-03-30 Takeda Chemical Industries, Ltd. Preparations a administrer par voie buccale a liberation lente
JP2000154137A (ja) 1998-09-18 2000-06-06 Takeda Chem Ind Ltd 徐放性経口製剤
EP1849475A1 (en) * 1999-06-21 2007-10-31 Eli Lilly & Company Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependent diabetes
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
EP1743655B1 (en) 2000-01-21 2014-06-25 Novartis AG Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US7078397B2 (en) * 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
EP1552832A1 (en) * 2002-07-11 2005-07-13 Takeda Pharmaceutical Company Limited Process for producing coated preparation
IN192749B (es) 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
JP4567340B2 (ja) * 2003-01-29 2010-10-20 武田薬品工業株式会社 被覆製剤の製造方法
EP1588708A4 (en) * 2003-01-29 2006-03-01 Takeda Pharmaceutical METHOD FOR PRODUCING COATED PREPARATION
CA2540225C (en) * 2003-10-31 2012-03-06 Takeda Pharmaceutical Company Limited Solid preparation of pioglitazone, glimepiride and a polyoxyethylene sorbitan fatty acid ester
JP4361461B2 (ja) 2003-10-31 2009-11-11 武田薬品工業株式会社 固形製剤
RU2766487C2 (ru) 2004-01-20 2022-03-15 Новартис Аг Композиция и способ прямого прессования
UA85871C2 (uk) * 2004-03-15 2009-03-10 Такеда Фармасьютікал Компані Лімітед Інгібітори дипептидилпептидази
AU2005299808B2 (en) 2004-10-25 2009-08-20 Novartis Ag Combination of DPP-IV inhibitor, PPAR antidiabetic and metformin
GT200600218A (es) 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
PT1931350E (pt) 2005-09-14 2014-02-12 Takeda Pharmaceutical Administração de inibidores de dipeptidil peptidase
TW200745079A (en) 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
AR058605A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Preparacion solida
JP5094416B2 (ja) * 2005-12-28 2012-12-12 武田薬品工業株式会社 糖尿病治療剤

Also Published As

Publication number Publication date
HRP20110094T1 (hr) 2011-03-31
ZA200905621B (en) 2010-10-27
BRPI0807453B1 (pt) 2021-01-05
EP2107905B1 (en) 2010-11-17
TW200836775A (en) 2008-09-16
DK2107905T3 (da) 2011-01-31
BRPI0807453A2 (pt) 2014-05-20
TN2009000317A1 (en) 2010-12-31
JP2010517937A (ja) 2010-05-27
HRP20110094T8 (en) 2011-07-31
GEP20125410B (en) 2012-02-27
US8637079B2 (en) 2014-01-28
DE602008003522D1 (de) 2010-12-30
JO2650B1 (en) 2012-06-17
TWI453041B (zh) 2014-09-21
RS51592B (sr) 2011-08-31
CA2677201A1 (en) 2008-08-07
EP2107905A1 (en) 2009-10-14
PT2107905E (pt) 2010-12-17
JP5284968B2 (ja) 2013-09-11
CR10992A (es) 2009-09-16
MX2009008100A (es) 2009-08-07
WO2008093882A1 (en) 2008-08-07
KR101486091B1 (ko) 2015-01-23
KR20090109115A (ko) 2009-10-19
AR065097A1 (es) 2009-05-13
CN101646420A (zh) 2010-02-10
PE20081663A1 (es) 2008-12-25
AU2008211981A1 (en) 2008-08-07
ME01239B (me) 2013-06-20
BRPI0807453B8 (pt) 2021-05-25
US20100092551A1 (en) 2010-04-15
TW201350143A (zh) 2013-12-16
MY147596A (en) 2012-12-31
CA2677201C (en) 2015-11-17
IL200108A (en) 2012-02-29
IL200108A0 (en) 2010-04-15
AU2008211981B2 (en) 2012-09-20
UA95828C2 (ru) 2011-09-12
SI2107905T1 (sl) 2011-03-31
CL2008000279A1 (es) 2008-08-18
MA31169B1 (fr) 2010-02-01
CY1111264T1 (el) 2015-08-05
CN101646420B (zh) 2012-11-07
ES2354397T3 (es) 2011-03-14
DOP2009000195A (es) 2009-08-31
HK1138188A1 (en) 2010-08-20
NZ579008A (en) 2012-02-24
EA200970726A1 (ru) 2010-02-26
EA015180B1 (ru) 2011-06-30
ATE488227T1 (de) 2010-12-15
PL2107905T3 (pl) 2011-04-29

Similar Documents

Publication Publication Date Title
ECSP099608A (es) Preparacion solida que comprende alogliptina y pioglitazona
DOP2010000028A (es) Preparacion solida que contiene alogliptina y clorhidrato de metformina
AR066130A1 (es) Formas cristalinas de saxagliptina y procesos para preparar las mismas
AR055060A1 (es) Derivados de n-(piridin-2-il)-sulfonamida
UY29384A1 (es) Derivados del ácido2-3s,4r)-4-(((3,4-dicloro-5-metil-1h-pirrol-2-il) carbonil)amino)-1,3-tiazol-5-carboxílico y sus sales, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciónes.
DOP2010000259A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
UY30759A1 (es) Compuestos quimicos
GT200800242A (es) Derivados biciclicos como inhibidores de cetp
AR112284A1 (es) Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico
AR124688A2 (es) Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
UY32126A (es) Composición farmacéutica sólida
ECSP10010659A (es) Derivados heterocíclicos de la urea y sus métodos de empleo
UY31864A (es) Derivados de urea hetericíclica y métodos de uso de los mismos-332
CO2024002748A2 (es) Profármaco de derivados de pirrolidona como activador de glucocinasa
AR057554A1 (es) Derivados de carbamoilbenzotriazol como inhibidores de lipasas y fosfolipasas
UY34916A (es) "preparación sólida que contiene ácido[(3s)-6-){2´,6´-dimetil-4´-[3-(metilsulfonil)propoxi]bifenil-3-il}metoxi)-2,3-dihidro-1-benzofuran-3-il]acético"
CL2018000391A1 (es) Combinaciones farmacéuticas y su uso
GT200500328A (es) Sal l-tartrato de n-1-adamantil-2-{3-[(2r)-2-({(2r)-2-hidroxi-2[4-hidroxi-3-(hidroximetil)fenil]etil}amino)propil]fenil}acetamida.
GT200600421A (es) Formas cristalinas polimórficas de la sal de di-sodio del ácido n-(5-clorosaliciloil)-8-aminocaprilico
ECSP078010A (es) Formulación de liberación prolongada de principios activos que presentan una solubilidad dependiente del ph
CL2021003152A1 (es) Una composición farmacéutica para la diabetes mellitus
GT200600012A (es) Compuestos farmaceuticos
PE20091464A1 (es) Formulacion farmaceutica de liberacion modificada que comprende oxabispidinas
AR054487A1 (es) Preparacion farmaceutica solida que contiene (r)-(-)-2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano